Thierry Van Nieuwenhove, CEO of Quotient Sciences, discusses the evolving landscape of Contract Development and Manufacturing Organizations (CDMOs).
Thierry emphasizes the shift in CDMO relationships with pharma and biotech clients from transactional models to more integrated, collaborative partnerships. This shift is not just about accelerating processes for speed but about creating a more controlled and responsive drug development process.
CDMOs that offer integrated services, and a collaborative approach are better positioned to help clients navigate uncertainty and use resources efficiently. Quotient Sciences uses its Translational Pharmaceutics® platform to enable greater agility by breaking down silos between traditionally separate functions.
Read the full article on the 247biopharma website.